

ACT-BT Referral Pro Forma

(Brain Tumour Clinical Trial Screening Referral)

About ACT-BT

ACT-BT (Access to Clinical Trials for Brain Tumours) is a national initiative that aims to improve awareness of, and access to, clinical trials for patients with brain tumours across the UK.

This referral pro forma enables clinicians to submit a patient's clinical information for review by the ACT-BT multidisciplinary panel. The panel meets weekly to assess whether there are any suitable UK clinical trials for which the patient may be eligible. The panel will offer advice and relevant contact information about specific studies.

Referral to ACT-BT does not guarantee that a suitable clinical trial will be identified. Although the panel may recommend to referral for a specific study it is ultimately a decision by the study team if the patient is eligible and if there is capacity to include them.

1. Patient Identification

Patient Name: _____

NHS Number: _____

Date of Birth: _____

Address: _____

2. Referrer Details

Referrer Name: _____

Consultant Registrar CNS Other

Organisation: _____

NHS Email Address (must be an NHS email address): _____

Alternative NHS Email Address (if different): _____

3. GP Information

GP Name: _____

GP Practice: _____

GP Contact Details: _____

4. Consent

ACT-BT Data Processing Consent: Yes No

*Patient has been informed that identifiable clinical information will be shared with the ACT-BT panel for discussion of potential clinical trial opportunities.

5. Demographics

Gender: Male Female Prefer not to say

Ethnicity: White Multiple ethnic groups Asian Black Other Prefer not to say

6. Clinical Status

Performance Status: 0 1 2 3 4

Estimated Life Expectancy: <3 months 3–6 months 6–12 months >12 months

7. Diagnosis & Pathology

Date of Diagnosis: _____

Primary Diagnosis: _____

Key Molecular Profile: _____

Initial Integrated Diagnostic Report Attached: Yes No

Most Recent Pathology Report Attached: Yes No

Additional Pathology / Genomic Reports Attached: Yes No

Whole Genome Sequencing (WGS) Available: Yes No

If relevant, is there important information contained within previous pathology reports? Yes No

8. Treatment History

SURGERY

Number of Previous Neurosurgical Procedures: 0 1 2 3+

Surgery 1 - Procedure: _____ Date: _____

Surgery 2 - Procedure: _____ Date: _____

Surgery 3 - Procedure: _____ Date: _____

Residual disease present after most recent surgery? Yes No Unknown

RADIOTHERAPY

Previous Radiotherapy: Yes No

Total Dose (Gy): _____

Month/Year of Last Radiotherapy: _____

Expected End Date (if ongoing): _____

SYSTEMIC ANTI-CANCER THERAPY

Regimen Date Received Last Treatment (MM/YYYY)

Treatment Ongoing? Yes No

Expected End Date (MM/YYYY): _____

Received as part of clinical trial? Yes No

Trial Name: _____

Tumour Treating Fields: Yes No

If yes, treatment dates (MM/YYYY): _____

OTHER CLINICAL TRIAL PARTICIPATION

Yes No

If yes, details: _____

9. Significant Treatment-Related Toxicities

Please include only toxicities likely to affect future treatment decisions, clinical trial eligibility, or treatment tolerability.

Associated Treatment: _____

Significant Toxicities: _____

10. Imaging

Latest imaging report attached (required): Yes No

Imaging Summary: _____

Other Relevant Investigations: _____

11. Medical Background

Significant Comorbidities: _____

Current Drug History: _____

Drug Allergies: _____

12. Clinical Query for Panel Discussion

Specific Questions / Objectives for Panel Discussion: _____

13. Additional Clinical Information

For ACT-BT team Use

Patient ACT-BT Reference Number: _____

14. Project Manager Review

Date Reviewed: _____

Initial Action:

Send to panel / Request additional information / Other

15. Chair Review Outcome

Date Reviewed: _____

Summary of Outcome:

List for discussion / Additional information required / Other

16. Panel Review Outcome

Date Reviewed: _____

Summary of Outcome:

Date Outcome Communicated: _____